Showing results (171-180 of 190) with videos related to

Sort By:
Pageof 19
RSC Advances|July 13, 2026
Synthesis and systematic evaluation of four stereoisomers of BMS compound A enabled by a diastereoselective cyclopropanation on a chiral ketal intermediateFeijun Wang, John N Hanson, Snezana T Dimova, et al.
The Journal of Infectious Diseases|September 20, 2022
Comparable Outcomes for Bebtelovimab and Ritonavir-Boosted Nirmatrelvir Treatment in High-Risk Patients With Coronavirus Disease-2019 During Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 Omicron EpochRaymund R Razonable, John C O'Horo, Sara N Hanson, et al.
Synapse (New York, N.Y.)|May 21, 1998
Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transportersA J Fischman, A A Bonab, J W Babich, et al.
Pharmacology, Biochemistry, and Behavior|March 29, 2001
Novel monoamine transporter ligands reduce cocaine-induced enhancement of brain stimulation rewardM Trzcińska, P Pimentel, J R Stellar, et al.
Mayo Clinic Proceedings|February 5, 2022
Effectiveness of Monoclonal Antibodies in Preventing Severe COVID-19 With Emergence of the Delta VariantJohn C O'Horo, Douglas W Challener, Leigh Speicher, et al.
JCI Insight|April 3, 2025
Germline mutations in PPP2R1B in patients with a personal and family history of cancerSahar Mazhar, Caitlin M O'Connor, Alexis Harold, et al.
Genome|September 12, 2001
Soybean genomic survey: BAC-end sequences near RFLP and SSR markersL F Marek, J Mudge, L Darnielle, et al.
Trials|February 11, 2023
The Michigan Genetic Hereditary Testing (MiGHT) study's innovative approaches to promote uptake of clinical genetic testing among cancer patients: a study protocol for a 3-arm randomized controlled trialLynette Hammond Gerido, Jennifer J Griggs, Ken Resnicow, et al.
Journal of the American Geriatrics Society|February 23, 2021
A mobile unit overcomes the challenges to monoclonal antibody infusion for COVID-19 in skilled care facilitiesSidna Tulledge-Scheitel, Sarah J Bell, Jennifer J Larsen, et al.
Mayo Clinic Proceedings|September 4, 2022
Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019Raymund R Razonable, John C O'Horo, Douglas W Challener, et al.
Pageof 19